Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | FASN | P49327 | 6/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18318321 | 0.99 | GSK3B (0.48) | GSK3BFASNMAPK14EPHX2PIK3CD | |
| SCHEMBL18331129 | 0.86 | GSK3B (0.47) | GSK3BFASNMAPK14PIK3CA | |
| SCHEMBL18321656 | 0.82 | GSK3B (0.53) | GSK3BFASNMAPK14 | |
| SCHEMBL18321675 | 0.82 | GSK3B (0.50) | GSK3BFASNMAPK14EPHX2 | |
| SCHEMBL18319381 | 0.82 | GSK3B (0.49) | GSK3BFASNEPHX2PIK3CDPIK3CA | |
| SCHEMBL18318741 | 0.82 | PIK3CA (0.51) | FASNPIK3CDPIK3CAPIK3CG | |
| SCHEMBL18321612 | 0.82 | GSK3B (0.49) | GSK3BFASNMAPK14EPHX2PIK3CD | |
| SCHEMBL31673855 | 0.82 | PIK3CA (0.51) | FASNPIK3CDPIK3CAPIK3CG | |
| SCHEMBL18322954 | 0.81 | FASN (0.49) | GSK3BFASNMAPK14EPHX2 | |
| SCHEMBL18318091 | 0.80 | FASN (0.47) | GSK3BFASNEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | claimed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | claimed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | claimed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | claimed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | claimed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GSK3B 3501/4885FASN 1/4885MAPK14 3489/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GSK3B 3501/4885FASN 1/4885MAPK14 3489/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | GSK3B 3501/4885FASN 1/4885MAPK14 3489/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GSK3B 3501/4885FASN 1/4885MAPK14 3489/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | GSK3B 3501/4885FASN 1/4885MAPK14 3489/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | GSK3B 3501/4885FASN 1/4885MAPK14 3489/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | GSK3B 3454/4885FASN 1/4885MAPK14 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.